Key Points
• Loss of RUNX1 by using genetic knockout or dominant-negative approaches leads to up-regulation of its direct target gene Hmga2 in HSPCs.
• Expansion of myeloid progenitors caused by the loss of RUNX1 is rescued by loss of Hmga2, suggesting that RUNX1 functions through Hmga2.
For personal use only. on April 12, 2017 . by guest www.bloodjournal.org From Introduction RUNX1, also known as AML1 and CBFα2, is a member of the Runt family of proteins. The major function of RUNX1 is to operate as a DNA binding transcription factor. Studies over the past 20 years have established RUNX1 as a critical player in hematopoiesis and specification of hematopoietic stem and progenitor cells (HSPCs), for neither process can occur without RUNX1 [1] [2] [3] . The importance of RUNX1 is further validated by its prevalence in a variety of hematological diseases and malignancies including myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPN), and multiple forms for acute myeloid leukemia (AML) [4] [5] [6] .
As a transcription factor, RUNX1 binds to DNA regulatory regions in order to guide the expression of its target genes. Most confirmed RUNX1 target genes are mainly expressed in differentiated blood cells 5, [7] [8] [9] . Direct targets of RUNX1 in HSPCs, however, have largely remained unexplored. The identification of these genes offers an insightful view into how this master regulator influences HSPC biology. To elucidate RUNX1 target genes in HSPCs, we performed genome-occupancy analysis with chromatin immunoprecipitation coupled with highthroughput sequencing (ChIP-seq) using RUNX1 antibodies and a murine HSPC cell line. This data was combined with gene expression signatures from wildtype and RUNX1-deficient HSPCs (Lineage-/cKit+/Sca1+) 10 . The combination of both sets of data allowed elucidation of Hmga2 as a RUNX1 target gene.
High mobility group AT-hook 2 (HMGA2) is a non-histone chromatin binding protein typically associated with enhancers but lacks its own transcriptional activity 11 . Its expression is generally highest in stem cells and during embryogenesis 12 . Aberrant HMGA2 expression has been associated with a variety of mesenchymal tumors including several examples in the hematopoietic system 13, 14 . Hence, HMGA2 is considered to be an oncogene. More recently,
For personal use only. on April 12, 2017 . by guest www.bloodjournal.org From ectopic expression of Hmga2 in transgenic mouse models or bone marrow transplantation with cells expressing Hmga2 have been demonstrated to result in myeloproliferatve disease 15, 16 . In these models, the HSPC populations are expanded as well as the myeloid progenitors. All of these studies suggest that HMGA2 serves as a critical regulator of proliferation and survival.
Conditional deletion of Runx1 in mice has allowed for the study of its role in HSPCs since mice that are null for Runx1 display embryonic lethality 1, 2, 17, 18 . Interestingly, one of the most striking phenotypes in Runx1 conditional knockout mice is a marked expansion of their HSPCs and myeloid progenitors 18, 19 . In this study, we identified Hmga2 as a target gene using RUNX1 ChIPseq and analyzed the role of RUNX1 in regulating Hmga2 expression. Furthermore, using genetic models of RUNX1 and HMGA2 deficiency, we establish that Hmga2 is a crucial regulator of myeloid progenitor expansion.
For personal use only. on April 12, 2017 Chromatin immunoprecipitation (ChIP) and sequencing ChIP procedure and antibody was previously described 21 . Approximately 5x10 7 EML cells were used to perform two replicates. High-throughput sequencing was conducted on a Genome
Analyzer II (Illumina, San Diego, USA) resulting in 2.7 x 10 7 and 2.6 x 10 7 reads. Sequences were aligned to the reference mouse genome (version mm9). Peak calling was performed using the MACS algorithm 22 . Peaks with a false discovery rate of less than 1% were associated with the closest transcriptional start site using PeakAnalyzer 23 . De novo motif finding was performed using the MEME software suite (http://meme.nbcr.net) 24 . Primers are provided in Table S1 .
RT-qPCR
RNA was extracted using the TRIzol method (Life Technologies, Carlsbad, USA) or RNeasy
Micro Plus kit (Qiagen, Venlo, Netherlands). cDNA was synthesized using Superscript III (Life Technologies). Primers are provided in Table S1 . 
Results

Hmga2 is a direct RUNX1 target gene in HSPCs
To gain further insight into which genes are directly regulated by RUNX1 in HSPCs, we performed RUNX1 ChIP-seq in the murine HSPC-like EML cell line. EML cells rely on stem cell factor for survival and has the capability of differentiating into the erythroid, myeloid, and lymphoid lineages 27 . Their multipotency and capacity to be grown in large cultures make the EML cell line an ideal cell system for ChIP-seq studies. Peak calling revealed 6370 peaks with a FDR of less than 1%. Interestingly, the location of the majority of peaks (73.3%) lay in regions more than 5 kilobases (kb) away from a transcriptional start site (TSS) ( Figure 1A ). Only a small percentage (10.8%) of peaks was in promoter regions, defined as 3 kb upstream of a TSS ( Figure 1B ). De novo motif analyses using the MEME suite revealed the most enriched motif to be TGTGGT, which is the known RUNX consensus motif ( Figure 1C ) 28 . Other top motifs correspond to the ETS and GATA family of transcription factors, both of which are also important players in hematopoiesis and further confirm that RUNX1 often works with these factors to exert its functions [29] [30] [31] [32] .
We previously reported the gene expression signatures of HSPCs (Lineage-/cKit+/Sca1+ or LSK cells) from wildtype, Runx1 conditional knockout ( Table 1 ). We also performed comparisons of our ChIP-seq data with other recently published RUNX1 ChIP-seq data ( Figure S1 ), which demonstrated further overlap of genes 31, 32 .
The combination of these data and comparisons has revealed a list of high potential RUNX1 target genes. Within this gene list, we decided first to focus our studies on HMGA2. Based on For personal use only. on April 12, 2017 . by guest www.bloodjournal.org From the published information of HMGA2, increased expression of HMGA2 is likely to result in similar cellular phenotypes as observed in RUNX1 deficiency. HMGA2 has been reported to play important roles in regulating cellular proliferation and cancer development 33, 13 . Our gene expression profiling data obtained from three biologically independent sets of RNA prepared from LSK cells indicate that Hmga2 expression is significantly increased ( Figure 2B ). Using RTqPCR studies, we demonstrated that Hmga2 transcript levels were 6-and 15-fold higher in
Runx1
Δ /Δ and RUNX1SF HSPCs, respectively, relative to wildtype controls ( Figure 2C ). In addition, Hmga2 is up-regulated in Runx1 Upon examination of the Hmga2 gene locus, ChIP-seq revealed RUNX1 binding regions in the promoter, upstream, downstream, and third intron regions ( Figure 2G ). All except the promoter region were determined to be significant by MACS 22 . These three significant RUNX1 binding regions are in agreement with recently published RUNX1 ChIP-seq data using murine HSPC lines 31 . The binding of RUNX1 to these regions were confirmed using ChIP-qPCR ( Figure   2H ). 34 . To study how RUNX1 regulates Hmga2 expression, a DNA fragment containing this region was inserted into the multiple cloning site of the pGLX promoterless luciferase reporter vector. The pGLX vector is a modified version of pGL2, which does not contain any RUNX consensus binding sites 26 . The cloned Hmga2
promoter DNA fragment has two RUNX consensus sites at bp -363 and -213 and a polypyrimidine/polypurine tract spanning bp -84 to -25, which gives the promoter much of its activity ( Figure 3A ) 34 . To examine whether RUNX1 affects Hmga2 promoter activity, we conducted transient transfection assays in non-hematopoietic cell lines (NIH3T3 and 293T) and hematopoietic cell lines (K562, Jurkat, and U937). In NIH3T3 and 293T cells, co-expression of the full length promoter with RUNX1 and its partner CBFβ reduces luciferase activity to 72% and 47%, respectively ( Figure 3B ). These results suggest that RUNX1 acts as a transcriptional repressor on the Hmga2 promoter in these two adherent cell lines. Interestingly, in the K562 and Jurkat leukemia cell lines, RUNX1 increases luciferase activity by 3-and 1.6-fold, respectively ( Figure 3C ). Since these cell lines represent erythromyeloid and lymphoid lineages, respectively, we also conducted experiments using U937 cells, which more closely represent monocyte/myeloid cells ( Figure 3C ). In this myeloid representative cell line, RUNX1 acts to suppress luciferase activity to 31%. Thus, RUNX1 regulates Hmga2 promoter activity in all of the cell lines tested, but acts on the promoter in a positive or negative manner depending on the cell and/or tissue type. Most importantly, RUNX1 acts as a transcriptional repressor of Hmga2 in myeloid cell types.
Since the Hmga2 promoter contains two RUNX consensus sites, we sought to ascertain whether these sites mediate RUNX1 interaction with the promoter by utilizing promoter constructs with these regions truncated or mutated. In NIH3T3 cells, mutation of either or both of the presumptive RUNX1 binding sites in the promoter does not abrogate the repression of For personal use only. on April 12, 2017 . by guest www.bloodjournal.org From luciferase upon co-expression of RUNX1 and CBFβ ( Figure 3D ). Constructs harboring truncations of the promoter at the 5' or 3' end also failed to affect RUNX1-mediated repression ( Figure S4 ). The same mutation constructs were used in U937 cells. The co-expression of RUNX1 and CBFβ was still able to repress luciferase activity with the three mutation constructs ( Figure 3E ). These results suggest that RUNX1 does not regulate the Hmga2 promoter through these two sites and likely exerts its effect by interacting with other intermediary factors that bind to the promoter. Given the ability of RUNX1 to interact with a variety of other transcriptional regulators 5 , this possibility seems likely regarding the regulation of Hmga2.
Runx1 intronic and intergenic binding regions mediate Hmga2 transcription
Significant RUNX1 binding regions were discovered in intronic and intergenic regions of Interestingly in NIH3T3 cells, addition of the upstream element induces enough transcriptional activation to counteract the repressive effect due to co-expression of RUNX1 and CBFβ ( Figure   4B ). For example, we no longer observe significant repression in the Promoter + Upstream case compared to Promoter alone. The same trends are observed using the same constructs in U937 cells ( Figure 4C ). Accordingly, the upstream element continues to result in heightened transcriptional activity in K562 cells ( Figure S6 ). Physical interaction between the upstream element and the promoter was confirmed by 3C-qPCR assay ( Figure 4D ). The increase in transcriptional activity induced by the upstream element, and confirmation of physical interaction
For personal use only. on April 12, 2017 . by guest www.bloodjournal.org From between the upstream element and the promoter suggests that it may potentially act as an enhancer element.
The downstream element was also tested in NIH3T3 and U937 cells. In both cell lines, the effect of co-expression of RUNX1 and CBFβ remained intact and did not differ significantly from the promoter element by itself. In U937 cells, the downstream element also added significantly more luciferase activity compared to promoter alone.
Finally, the constructs containing the intron element with the Hmga2 promoter were used for promoter-luciferase assays. In contrast to the upstream element, the intron element significantly represses basal luciferase activity relative to the full length promoter in all of the cell lines tested ( Figure 4B-C) . In NIH3T3 and U937 cells, the promoter and intron construct continues to result in transcriptional repression when co-expressed with RUNX1 and CBFβ ( Figure 4B ). In K562 cells, addition of the intron element induces enough transcriptional repression to counteract the activation due to co-expression of RUNX1 and CBFβ ( Figure S6 ).
Similar to the case of the Promoter + Upstream element in NIH3T3 cells where the trend of repression is still observed but no longer significant, in K562 cells the activation due to coexpression of RUNX1 and CBFβ is still observed but no longer significant. These results suggest that the upstream and intron regions are enhancer and silencer elements, respectively.
HMGA2 does not modulate the effect of RUNX1 deficiency on HSPC expansion
Our current studies indicate that Hmga2 expression is directly regulated by RUNX1 and that Hmga2 expression is significantly increased in HSPCs in the absence of RUNX1 or in the presence of RUNX1SF (Figure 2) . One of the most dramatic phenotypes of Runx1 Δ /Δ mice and RUNX1SF mice is expansion of their HSPC populations 10, 17, 18 . HMGA2 is generally thought to be a proliferation-inducing factor. Transgenic mice expressing Hmga2 and over-expression of does not affect HSPC expansion due to the deficiency of RUNX1.
In addition, the common lymphoid progenitor (CLP) populations were assessed.
Although we observed a trend toward higher frequencies of CLPs in the absence of RUNX1, this difference was not significant ( Figure 5E ). In addition, neither Hmga2 -/-nor Double KO mice exhibited any significant differences in CLP frequency.
The HSPCs in Runx1
Δ /Δ mice have been described to have lower levels of apoptosis overall 35 . In addition, ectopic expression of Hmga2 has also been demonstrated to lead to lower levels of apoptosis 36 . To ascertain whether Hmga2 has any role in mediating apoptosis in the context of RUNX1 loss-of-function, we examined the frequency of apoptosis in LSK cells by using Annexin V staining ( Figure 5F ). Hmga2 -/-and Double KO mice exhibited higher levels while Runx1 Δ /Δ mice generally exhibited lower levels of Annexin V-positive cells, demonstrating that Hmga2 plays an important role in regulating apoptosis in this population and that it is necessary for the decreased apoptosis associated with loss of RUNX1.
For
Hmga2 contributes to myeloid progenitor expansion caused by the loss of RUNX1
Another major phenotype of Runx1 Δ /Δ mice is their expansion of the myeloid progenitors, specifically the GMP and CMP populations 18, 19 . Intriguingly, the role of HMGA2 in inducing proliferation in the hematopoietic system has primarily been biased towards the myeloid lineage 15, 16 . To test the involvement of HMGA2 in regulating myeloid progenitors in RUNX1-deficient mice, we analyzed the bone marrow compartments of wildtype, Hmga2 -/-, Runx1 For
Discussion
RUNX1 has been implicated in a variety of blood-related diseases and neoplasms 5 .
Many of these diseases originate from mutations in RUNX1 that occur at the stage of the HSPC and result in the loss of normal RUNX1 function. As a transcription factor, the primary biological activity of RUNX1 is to control the expression of its target genes. The goal of this study was to determine which genes RUNX1 directly targets at the level of the HSPC and whether those genes have any functions in regulating HSPCs. To this end, we used a combination of differential gene expression analyses and genome-wide transcription factor occupancy to identify prospective RUNX1 direct targets. For gene expression analyses, two models of RUNX1 deficiency were employed-an inducible conditional knockout model for RUNX1, and a bone marrow transplantation model employing RUNX1SF as a dominant-negative regulator of endogenous RUNX proteins. To elucidate DNA occupancy of RUNX1 on a genome-wide scale, ChIP-seq was conducted on a HSPC-like cell line using RUNX1 antibody. The result was a condensed list of high potential direct target genes that are regulated by RUNX1 at the level of the HSPC (Table 1 ). The prospect of modulating the activity of these genes provides potential candidates for creating therapies against diseases caused by the loss of RUNX1 function, and offers an intriguing look into the mechanisms of how perturbed RUNX1 function may result in disease.
All of these genes have diverse roles in mediating various functions both inside and outside of the hematological system. Briefly, Csf2rb codes for the common beta chain subunit found in the GM-CSF, IL-3, and IL-5 receptors and is important in regulating specific cytokine responses 37 . Gzmb and Igf2r have both been implicated in regulating cytotoxic T-cell-mediated apoptosis 38 . Lcp2 is necessary for T-cell development 39 . Identification of which partner factor(s) RUNX1 interacts with in these various contexts is a topic of ongoing study.
For the first time, distal regulatory regions in and around the Hmga2 locus were demonstrated to have effects on Hmga2 expression. Interestingly, the effects exerted by the upstream and intron regions were constant and did not depend on the cell type in which they were tested. When these regions were added to the promoter-luciferase assays, the upstream For personal use only. on April 12, 2017 . by guest www.bloodjournal.org From and intron regions were associated with transcriptional activation and repression, respectively, but did not affect RUNX1-mediated transcription specific to each cell line tested. Hence, the upstream and intron regions most likely serve as enhancer and silencers of Hmga2, respectively. Another possibility is that RUNX1 binding to these regulatory elements contributes to the regulation of endogenous Hmga2 gene expression in HSPCs. Under conditions of transient transfection, however, the relatively higher levels of exogenous RUNX1 expression is sufficient for binding with its collaborating factors at the Hmga2 proximal promoter region which may overwhelm its effects from the binding to these other regulatory regions.
In addition to demonstrating that Hmga2 is a transcriptional target of RUNX1, we showed that it contributes to GMP and CMP expansion resulting from loss of RUNX1 function.
Importantly, the GMP population has often been associated with harboring leukemia stem cells (LSCs) in a variety of different leukemias [44] [45] [46] . A recent study focused specifically on the RUNX1-ETO (RE) fusion protein described the ability of RE to induce expansion of the GMP population and that the GMP RUNX1-ETO-expressing population can induce a leukemia-like state in an in vivo mouse model 46 . Loss of RUNX1 in various conditional knockout models has also been shown to expand both the GMP and CMP populations and induce altered hematopoietic states 18, 19 . Hence, loss of RUNX1 function either through mutation or by involvement in chromosomal translocation leads to an increase of cells capable of eventually transitioning to leukemia. Without RUNX1 acting as a tumor suppressor, Hmga2 is allowed to become up-regulated to induce a pre-malignant state. Limiting the expansion of GMPs by decreasing or regulating the amounts of HMGA2 may provide another method of controlling leukemia progression through keeping the number of LSCs in check.
Various cases of HMGA2 disruption associated with hematological disease have been described and are typically associated with perturbing the myeloid lineages [47] [48] [49] . Notably, some mutations result in truncation of the 3' untranslated region of HMGA2. This region of HMGA2 Conflict-of-interest disclosure: The authors declare no competing financial interests.
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